|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Precision medicine in gastric cancer显示文摘Gastric cancer(GC)is a complex disease linked to a series of environmental factors and unhealthy lifestyle habits,and especially to genetic alterations.GC represents the second leading cause of cancer-related deaths worldwide.Its onset is subtle,and the majority of patients are diagnosed once the cancer is already advanced.In recent years,there have been innovations in the management of advanced GC including the introduction of new classifications based on its molecular characteristics.Thanks to new technologies such as next-generation sequencing and microarray,the Cancer Genome Atlas and Asian Cancer Research Group classifications have also paved the way for precision medicine in GC,making it possible to integrate diagnostic and therapeutic methods.Among the objectives of the subdivision of GC into subtypes is to select patients in whom molecular targeted drugs can achieve the best results;many lines of research have been initiated to this end.After phase III clinical trials,trastuzumab,anti-Erb-B2 receptor tyrosine kinase 2(commonly known as ERBB2)and ramucirumab,anti-vascular endothelial growth factor receptor 2(commonly known as VEGFR2)monoclonal antibodies,were approved and introduced into first-and second-line therapies for patients with advanced/metastatic GC.However,the heterogeneity of this neoplasia makes the practical application of such approaches difficult.Unfortunately,scientific progress has not been matched by progress in clinical practice in terms of significant improvements in prognosis.Survival continues to be low in contrast to the reduction in deaths from many common cancers such as colorectal,lung,breast,and prostate cancers.Although several target molecules have been identified on which targeted drugs can act and novel products have been introduced into experimental therapeutic protocols,the overall approach to treating advanced stage GC has not substantially changed.Currently,surgical resection with adjuvant or neoadjuvant radiotherapy and chemotherapy are the most effective treatments for this disease.Future research should not underestimate the heterogeneity of GC when developing diagnostic and therapeutic strategies aimed toward improving patient survival. | Patrizia Bonelli Antonella Borrelli Franca Maria Tuccillo Lucrezia Silvestro Raffaele Palaia Franco Maria Buonaguro | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 8 |
| 2 | 乳房体积测量方法的比较研究显示文摘目的比较各类乳房体积测量方法,为临床应用提供参考。方法以'breast volume'、'breast measurement'和'breast volumetry'为关键词,检索Pubmed和万方数据库,筛选出以乳房体积测量为主题的文献。回顾、整理各类乳房体积测量方法,并分析其原理,比较其准确性、经济性和操作可行性。结果自1970年7月至2013年5月,总共有46篇以乳房体积测量的文章符合入选标准。目前已被报道的乳房体积测量方法共有9种,可以根据其测量原理分为三类:影像法,包括MRI、超声和CT测量;自然法,包括3D建模、排水体积法和胸模法;几何法,包括Grossman-Roudner、人体测量计算和X线摄片。结论 9种测量方法中,3D建模和MRI测量法,因准确性较高,又没有明显的副作用,可以用来为术前计划提供参考;Grossman-Roudner模具测量法和人体测量法虽可靠性有所降低,但经济简便,可以使用在较大样本量的临床研究中。 | 喜雯婧 闵沛如 苏薇洁 冯少清 Aurelia Trisliana 张艳 濮哲铭 章一新 Lucrezia Pacchioni | 2013 | 组织工程与重建外科杂志2013，9，6： | 7 |
| 3 | HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption显示文摘 | Ioanna Papandreou Rob A. Cairns Lucrezia Fontana Ai Lin Lim Nicholas C. Denko | 2006 | Cell Metabolism2006，，3： | 2 |
| 4 | Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?显示文摘AIM To evaluate the prevalence of nodular lymphoid hyperplasia(NLH) in adult patients undergoing colonoscopy and its association with known diseases. METHODS We selected all cases showing NLH at colonoscopy in a three-year timeframe, and stratified them into symptomatic patients with irritable bowel syndrome(IBS)-type symptoms or suspected inflammatory bowel disease(IBD), and asymptomatic individuals undergoing endoscopy for colorectal cancer screening.Data collection included medical history and final diagnosis. As controls, we considered all colonoscopies performed for the aforementioned indications during the same period.RESULTS One thousand and one hundred fifty colonoscopies were selected. NLH was rare in asymptomatic individuals(only 3%), while it was significantly more prevalent in symptomatic cases(32%). Among organic conditions associated with NLH, the most frequent was IBD, followed by infections and diverticular disease. Interestingly, 31% of IBS patients presented diffuse colonic NLH. NLH cases shared some distinctive clinical features among IBS patients: they were younger, more often female, and had a higher frequency of abdominal pain, bloating, diarrhoea, unspecific inflammation, self-reported lactose intolerance and metal contact dermatitis. CONCLUSION About 1/3 of patients with IBS-type symptoms or suspected IBD presented diffuse colonic NLH, which could be a marker of low-grade inflammation in a conspicuous subset of IBS patients. | Anna Chiara Piscaglia Lucrezia Laterza Valentina Cesario Viviana Gerardi Rosario Landi Loris Riccardo Lopetuso Giovanni Calò Giovanna Fabbretti Massimo Brisigotti Maria Loredana Stefanelli Antonio Gasbarrini | 2016 | World Journal of Gastroenterology2016，22，46： | 2 |
| 5 | Colorectal cancer metastatic to the breast:A case report显示文摘BACKGROUND Breast metastases from colorectal cancer(CRC)are very uncommon.There is no unanimous consensus regarding the best treatment for this rare condition,and management is,especially in elderly patients,limited to diagnosis and palliative care.Capecitabine,an oral fluoropyrimidine derivative,might be helpful in controlling the disease and may be a treatment option for patients unable to receive more aggressive chemotherapy.CASE SUMMARY We report a case of synchronous massive breast metastasis from CRC in an 85 year old patient who came to the hospital presenting a huge mass originating from the axillary extension of the right breast.A whole body computed tomography also showed a mass in the right colon.The patient underwent a simple right mastectomy along with right hemicolectomy.The resected breast showed massive metastasis from CRC with intense and homogeneous nuclear CDX2 staining,while the colon specimen revealed poorly differentiated adenocarcinoma stage pT4a pN0 pM1(breast)(Tumor Node Metastasis 2017).Three months later she developed a subcutaneous mass at the site of the previous mastectomy.An ultrasound guided biopsy was carried out again and revealed a metastasis from CRC.The patient then started treatment with capecitabine plus bevacizumab,obtaining stable disease(RECIST criteria)and a clinical benefit after 3 mo of therapy.CONCLUSION In our experience,capecitabine and bevacizumab may be a useful treatment option for breast metastases from primary CRC in elderly patients. | Silvia Taccogna Elisa Gozzi Luigi Rossi Davide Caruso Davide Conte Patrizia Trenta Valentina Leoni Silverio Tomao Lucrezia Raimondi Francesco Angelini | 2020 | World Journal of Gastrointestinal Oncology2020，12，9： | 2 |
| 6 | Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility显示文摘 | Franco Scaldaferri Viviana Gerardi Loris Riccardo Lopetuso Fabio Del Zompo Francesca Mangiola Ivo Bo?koski Giovanni Bruno Valentina Petito Lucrezia Laterza Giovanni Cammarota Eleonora Gaetani Alessandro Sgambato Antonio Gasbarrini Michael Mahler | 2013 | BioMed Research International2013，，： | 2 |
| 7 | A型肉毒毒素额部除皱后引起皮脂分泌改变的实验研究显示文摘目的:观察比较两种不同注射剂量的A型肉毒毒素(BTX-A)行额部注射除皱术后,引起局部皮脂分泌改变的情况,并研究其剂量和功效之间的关联。方法20例额部皱纹患者(中度至重度)随机分为注射总量10 U或20 U的两个治疗组。注射药物为宝妥适(BOTOX, BOTOX Cosmetic;Allergan, Irvine, CA),使用肌肉内注射标准五点法。评价注射后2周、4周、8周、16周患者额部注射区域(注射点外围半径0.5 cm区域、注射点外围半径0.6~1.5 cm环形区域、注射点外围半径1.6~2.5 cm环形区域)皮肤油脂分泌水平。结果两种不同剂量注射2周、4周、8周后额部注射点外围半径0.5 cm区域平均皮脂分泌水平较注射前显著下降(P<0.05),注射16周后注射点外围半径0.5 cm区域平均油脂分泌水平于注射前相比没有显著差异。注射2周、4周、8周、16周后,注射点外围半径1.6~2.5 cm环形区域皮肤的平均油脂分泌水平显著高于注射前平均皮肤油脂分泌水平(P<0.05),注射点外围半径1.6~2.5 cm环形区域皮肤的平均油脂分泌水平与注射前水平相比没有显著的统计学差异。结论10 U及20 U肌肉内BTX-A注射2周、4周及8周后,能显著减少注射点外围半径0.5 cm区域的皮脂分泌,并引起注射点外围半径1.6~2.5 cm环形区域皮肤的皮脂分泌增高。 | 闵沛如 喜雯婧 苏薇洁 冯少清 Aurelia Trisliana 濮哲铭 张艳 章一新 Lucrezia Pacchioni | 2013 | 组织工程与重建外科杂志2013，9，6： | 2 |
| 8 | Large Bayesian Vector Auto Regressions 显示文摘 | Marta Banbura Domenico Giannone Lucrezia Reichlin | 2010 | Journal of Applied Econometrics2010，25，1： | 1 |
| 9 | Giardia lamblia Infections become Clinically Evident by Eliciting Symptoms of Irritable Bowel Syndrome显示文摘 | Marco D’Anchino Dante Orlando Lucrezia De Feudis | 2002 | Journal of Infection2002，，3： | 1 |
| 10 | Performance Measurement of the After-sales Service Network--Evidence from the Auto- motive Industry显示文摘 | Paolo G Nicola S Lucrezia S | 2007 | Computers in Industry2007，58，7： | 1 |
| 11 | The Generalized Dynamic Factor Model: Identification and Estimation 显示文摘 | Forni Mario Marc Hallin Marco Lippi and Lucrezia Reichlin | 2000 | Review of Economics and Statistics2000，825，： | 1 |
| 12 | Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?显示文摘 | Lucrezia Silvestro Guglielmo Nasti Alessandro Ottaiano Massimo Montano Rossana Casaretti Antonio Avallone Massimiliano Berretta Carmela Romano Antonio Cassata Salvatore Tafuto Rosario Vincenzo Iaffaioli | 2013 | Anti-Cancer Agents in Medicinal Chemistry2013，，9： | 1 |
| 13 | A Specialized Vascular Niche for Adult Neural Stem Cells显示文摘 | Masoud Tavazoie Lieven Van der Veken Violeta Silva-Vargas Marjorie Louissaint Lucrezia Colonna Bushra Zaidi Jose Manuel Garcia-Verdugo Fiona Doetsch | 2008 | Cell Stem Cell2008，，3： | 1 |
| 14 | Paint on the finger or paint on the screen a comparative study显示文摘 | CRESCENZI LUCREZIA PRICE SARA JEWITF CAREY | 2014 | Procedia-sociai and Behavioral Sciences2014，140，： | 1 |
| 15 | Performance measurement of the after-sales service network—Evidence from the automotive industry显示文摘 | Paolo Gaiardelli Nicola Saccani Lucrezia Songini | 2007 | Computers in Industry2007，，7： | 1 |
| 16 | Immunolocalization of corticotropin-releasing factor (CRF) and corticotropin-releasing factor receptor 2 (CRF-R2) in the developing gut of the sea bass ( Dicentrarchus labrax L.)显示文摘 | Lucrezia Mola Andrea Gambarelli Aurora Pederzoli | 2009 | Acta Histochemica2009，，3： | 1 |
| 17 | Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases显示文摘AIM:To assess clinical and endoscopic response to propionyl-L-carnitine hydrochloride(PLC) in colonic inflammatory bowel disease.METHODS:Patients suffering from mild to moderate ulcerative colitis(UC) or Crohn's disease(CD) colitis,with disease activity index(DAI) between 3 and 10 and under stable therapy with oral aminosalicylates,mercaptopurine or azathioprine,for at least 8 wk prior to baseline assessments,were considered suitable for enrollment.Fourteen patients were enrolled to assume PLC 2 g/d(two active tablets twice daily) orally.Clinical-endoscopic and histological activity were assessed by DAI and histological index(HI),respectively,following a colonoscopy performed immediately before and after 4 wk treatment.Clinical response was defined as a lowering of at least 3 points in DAI and clinical remission as a DAI score ≤ 2.Histological response was defined as an improvement of HI of at least 1 point.We used median values for the analysis.Differences pre-and post-treatment were analyzed by Wilcoxon signed rank test.RESULTS:All patients enrolled completed the study.One patient,despite medical advice,took deflazacort 5 d before follow-up colonoscopy examination.No side effects were reported by patients during the trial.After treatment,71%(SE 12%) of patients achieved clinical response,while 64%(SE 13%) obtained remission.Separating UC from CD patients,we observed a clinical response in 60%(SE 16%) and 100%,respectively.Furthermore 60%(SE 16%) of UC patients and 75%(SE 25%) of CD patients were in clinical remission after therapy.The median DAI was 7 [interquartile range(IQR):4-8] before treatment and decreased to 2(IQR:1-3)(P < 0.01) after treatment.Only patients with UC showed a significant reduction of DAI,from a median 6.5(IQR:4-9) before treatment to 2(IQR:1-3) after treatment(P < 0.01).Conversely,in CD patients,although displaying a clear reduction of DAI from 7(IQR:5.5-7.5) before therapy to 1.5(IQR:0.5-2.5) after therapy,differences observed were not significant(P = 0.06).Seventy-nine percent(SE 11%) of patients showed improvement of HI of at least 1 point,while only one CD and two UC patients showed HI stability;none showed HI worsening.Median HI decreased from 1(IQR:1-2),to 0.5(IQR:0-1) at the endoscopic control in the whole population(P < 0.01),while it changed from 1(IQR:1-2) to 0.5(IQR:0-1) in UC patients(P < 0.01) and from 1.5(IQR:1-2) to 0.5(IQR:0-1) in CD patients(P = not significant).The two sample tests of proportions showed no significant differences in clinical and histological response or in clinical remission between UC and CD patients.No side effects were reported during treatment or at 4 wk follow-up visit.CONCLUSION:PLC improves endoscopic and histological activity of mild to moderate UC.Further studies are required to evaluate PLC efficacy in colonic CD patients. | Giuseppe Merra Giovanni Gasbarrini Lucrezia Laterza Marco Pizzoferrato Andrea Poscia Franco Scaldaferri Vincenzo Arena Francesca Fiore Achille Cittadini Alessandro Sgambato Francesco Franceschi Antonio Gasbarrini | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 18 | How much more rain will global warming bring?显示文摘 | Frank J W Lucrezia R Kyle H | 2007 | Science2007，317，： | 1 |
| 19 | Polyhydroxyalkanoates production with mixed microbial cultures: from culture selection to polymer recovery in a high-rate continuous process显示文摘 | Marianna Villano Francesco Valentino Andrea Barbetta Lucrezia Martino Mariastella Scandola Mauro Majone | 2014 | New BIOTECHNOLOGY2014，，4： | 1 |
| 20 | The Dynamic Effects of Aggregate Demand and Supply Disturbances: Comment 显示文摘 | Marco Lippi Lucrezia Reichlin | 1993 | American Economic Review1993，83，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员